Compare Abeona Therapeutics Inc (ABEO) vs Icl Group Ltd (ICL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Icl Group Ltd — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Icl Group Ltd trades at $5.08 (market cap $6.49B). The key difference: Icl Group Ltd is far larger — about 17.4× Abeona Therapeutics Inc's market cap, and Icl Group Ltd pays a 3.85% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | ICL | |
|---|---|---|
Market Cap | $373.32M | $6.49B |
Sector | Health | Basic Materials |
52-Week High | $7.23 | $7.23 |
52-Week Low | $4.17 | $4.80 |
Enterprise Value | $228.22M | $9.06B |
Dividend Yield | — | 3.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
ICL trades at $4.95, down 1.59% on the day, with a bearish technical signal. The company reported Q1 2026 earnings of $0.11 per share, beating estimates, and announced a $0.05 dividend for H1 2026. Revenue for 2025 was $7.15B with a net income margin of 3.52%, while valuation metrics show a P/E of 24.05 and P/S of 0.88. Recent news highlights the completion of an $800 million senior notes offering to manage debt.
The outlook is mixed; strong cash flow and dividend payments provide stability, but declining profit margins and bearish analyst sentiment pose risks. Investment opportunity lies in operational improvements and potash market exposure, though investors face headwinds from raw material costs and foreign exchange volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →
